6-(prop-2-yn-1-yloxy)-2-naphthaldehyde

• 分子结构分类: 有机化合物 - 苯类化合物 - 萘
• 英文名称: 6-(prop-2-yn-1-yloxy)-2-naphthaldehyde
• 英文别名: 6-Prop-2-ynoxynaphthalene-2-carbaldehyde；6-prop-2-ynoxynaphthalene-2-carbaldehyde
• 化学式: C₁₄H₁₀O₂
• 分子量: 210.232
• InChiKey: AKHOVRXZAQJMHM-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.7
• 重原子数：
  16
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.07
• 拓扑面积：
  26.3
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  6-(prop-2-yn-1-yloxy)-2-naphthaldehyde 在 N-溴代丁二酰亚胺(NBS) 、 sodium hydride 、 N,N-二异丙基乙胺 作用下， 以 乙醇 、 N,N-二甲基甲酰胺 为溶剂， 反应 0.99h， 生成 5-amino-1-(tert-butyl)-3-(6-(prop-2-yn-1-yloxy)naphthalen-2-yl)-1H-pyrazole-4-carboxamide
  参考文献：
  名称：

  Development of 5-Aminopyrazole-4-carboxamide-based Bumped-Kinase Inhibitors for Cryptosporidiosis Therapy

  摘要：

  Cryptosporidium is a leading cause of pediatric diarrhea worldwide. Currently, there is neither a vaccine nor a consistently effective drug available for this disease. Selective 5-aminopyrazole-4-carboxamide-based bumped-kinase inhibitors (BKIs) are effective in both in vitro and in vivo models of Cryptosporidium parvum. Potential cardiotoxicity in some BKIs led to the continued exploration of the 5-aminopyrazole-4-carboxamide scaffold to find safe and effective drug candidates for Cryptosporidium. A series of newly designed BKIs were tested for efficacy against C. parvum using in vitro and in vivo (mouse infection model) assays and safety issues. Compound 6 (BKI 1708) was found to be efficacious at 8 mg/kg dosed once daily (QD) for 5 days with no observable signs of toxicity up to 200 mg/kg dosed QD for 7 days. Compound 15 (BKI 1770) was found to be efficacious at 30 mg/kg dosed twice daily (BID) for 5 days with no observable signs of toxicity up to 300 mg/kg dosed QD for 7 days. Compounds 6 and 15 are promising preclinical leads for cryptosporidiosis therapy with acceptable safety parameters and efficacy in the mouse model of cryptosporidiosis.

  DOI：

  10.1021/acs.jmedchem.9b00069
• 作为产物：
  描述：

  6-羟基-2-萘甲醛 、 3-溴丙炔 在 potassium carbonate 作用下， 以 乙腈 为溶剂， 反应 3.0h， 以76%的产率得到6-(prop-2-yn-1-yloxy)-2-naphthaldehyde
  参考文献：
  名称：

  多组氨酸移植导致鱼骨状结构†

  摘要：

  合成了一小部分 Morita-Baylis-Hillman 加合物 (MBHA) 衍生物，并使其与咪唑、N-乙酰组氨酸和N-乙酰六组氨酸反应作为多组氨酸衍生物的模型。有趣的是，MBHA 衍生物1a和b与咪唑在乙腈-磷酸盐缓冲盐水 (PBS) 中的反应得到咪唑盐双加合物3a和b作为主要反应产物。这些结果通过用N-乙酰组氨酸和1b进行的实验得到证实，并表明这些结构可能出现在用 MBHA 衍生物1a和 1a和乙。然后通过引入低聚（乙二醇）链将这些化合物转化为相应的水溶性衍生物1c-e ，并在 PBS 中的咪唑和N-乙酰基六组氨酸的初步实验中评估它们的反应性。使用十倍过量的化合物1d和e获得的聚合物材料Ac-His-6-MBHA-1d和Ac-His-6-MBHA-1e的结构使用质谱、核磁共振光谱和光物理研究进行了研究，这表明两种聚合物材料中都存在双加合物残基。这些结果为制备鱼骨状聚合物刷、表征其性

  DOI：

  10.1039/c8ra00315g

文献信息

• Poly-histidine grafting leading to fishbone-like architectures
  作者：Vincenzo Razzano、Marco Paolino、Annalisa Reale、Germano Giuliani、Alessandro Donati、Gianluca Giorgi、Roberto Artusi、Gianfranco Caselli、Michela Visintin、Francesco Makovec、Salvatore Battiato、Filippo Samperi、Francesca Villafiorita-Monteleone、Chiara Botta、Andrea Cappelli

  DOI：10.1039/c8ra00315g

  日期：——

  with imidazole, N-acetylhistidine, and N-acetylhexahistidine as models of poly-histidine derivatives. Intriguingly, the reaction of MBHA derivatives 1a and b with imidazole in acetonitrile–phosphate buffered saline (PBS) gave the imidazolium salt biadducts 3a and b as the main reaction products. These results were confirmed by experiments performed with N-acetylhistidine and 1b and suggested the possible

  合成了一小部分 Morita-Baylis-Hillman 加合物 (MBHA) 衍生物，并使其与咪唑、N-乙酰组氨酸和N-乙酰六组氨酸反应作为多组氨酸衍生物的模型。有趣的是，MBHA 衍生物1a和b与咪唑在乙腈-磷酸盐缓冲盐水 (PBS) 中的反应得到咪唑盐双加合物3a和b作为主要反应产物。这些结果通过用N-乙酰组氨酸和1b进行的实验得到证实，并表明这些结构可能出现在用 MBHA 衍生物1a和 1a和乙。然后通过引入低聚（乙二醇）链将这些化合物转化为相应的水溶性衍生物1c-e ，并在 PBS 中的咪唑和N-乙酰基六组氨酸的初步实验中评估它们的反应性。使用十倍过量的化合物1d和e获得的聚合物材料Ac-His-6-MBHA-1d和Ac-His-6-MBHA-1e的结构使用质谱、核磁共振光谱和光物理研究进行了研究，这表明两种聚合物材料中都存在双加合物残基。这些结果为制备鱼骨状聚合物刷、表征其性
• Harmonizing Topological Features of Self-Assembled Fibers by Rosette-Mediated Random Supramolecular Copolymerization and Self-Sorting of Monomers by Photo-Cross-Linking
  作者：Sho Takahashi、Shiki Yagai

  DOI：10.1021/jacs.2c05484

  日期：2022.7.27

  elongated fibers. Supramolecular copolymerization of the two monomers is achieved by cooling hot monomer mixtures in a nonpolar solvent, which results in the formation of thermodynamically stable spirally folded yet elongated fibers. Atomic force microscopic observations and theoretical simulations of the experimental data obtained by absorption spectroscopy reveal the homopolymerization of the diace

  无规共聚是通过协调不同单体的不同性质来合成所需聚合物的有效方法。对于单体结合本质上是动态的超分子聚合物，由于自识别（自分选）时的焓优势，难以实现具有不同分子结构和性质的单体的无规共聚。在这里，我们展示了一个热力学控制的无规超分子共聚的例子，通过形成六元氢键花环中间体，用巴比妥酸官能化的两种单体，以展示两个主链基序的结构协调，即内在弯曲和线性基序. 一种基于萘发色团的单体专门形成环形纤维，而另一种带有额外的光反应性二乙炔部分则提供线性拉长的纤维。两种单体的超分子共聚是通过在非极性溶剂中冷却热的单体混合物来实现的，这导致形成热力学稳定的螺旋折叠但伸长的纤维。原子力显微镜观察和通过吸收光谱获得的实验数据的理论模拟揭示了联乙炔官能化单体在高温区域均聚，随后萘单体在中温区域掺入形成超分子共聚物随机单体序列。最后，
• Polymer and composition for forming organic film, substrate for manufacturing semiconductor apparatus, method for forming organic film, and patterning process
  申请人：SHIN-ETSU CHEMICAL CO., LTD.

  公开号：US10998197B2

  公开（公告）日：2021-05-04

  The invention provides a composition for forming an organic film, which generates no by-product even under such a film formation condition in an inert gas to prevent substrate corrosion, which is capable of forming an organic film not only excellent in properties of filling and planarizing a pattern formed on a substrate but also favorable for dry etching resistance during substrate processing, and further which causes no fluctuation in film thickness of the film due to thermal decomposition even when a CVD hard mask is formed on the organic film. The composition for forming an organic film includes (A) a polymer having a repeating unit shown by the following general formula (1) and (B) an organic solvent.

  本发明提供了一种用于形成有机薄膜的组合物，该组合物即使在惰性气体中的成膜条件下也不会产生副产物，以防止基底腐蚀；该组合物不仅能够形成在基底上形成的图案的填充和平面化性能优异的有机薄膜，而且在基底加工过程中还有利于耐干蚀刻；此外，即使在有机薄膜上形成 CVD 硬掩膜，也不会因热分解而导致薄膜厚度波动。用于形成有机薄膜的组合物包括 (A) 具有以下通式 (1) 所示重复单元的聚合物和 (B) 有机溶剂。
• Composition for forming organic film, substrate for manufacturing semiconductor apparatus, method for forming organic film, patterning process, and polymer
  申请人：SHIN-ETSU CHEMICAL CO., LTD.

  公开号：US11181821B2

  公开（公告）日：2021-11-23

  The invention provides a composition for forming an organic film, which generates no by-product even under such a film formation condition in an inert gas to prevent substrate corrosion, which is capable of forming an organic film not only excellent in properties of filling and planarizing a pattern formed on a substrate but also favorable for dry etching resistance during substrate processing, and further which causes no fluctuation in film thickness of the film due to thermal decomposition even when a CVD hard mask is formed on the organic film. The composition for forming an organic film includes (A) a polymer having a repeating unit shown by the following general formula (1) and (B) an organic solvent.

  本发明提供一种用于形成有机膜的组合物，即使在惰性气体中形成薄膜以防止基底腐蚀，也不会产生副产品。该组合物形成的有机膜不仅在填充和平面化基底上的图案方面表现出优异的特性，而且在基底处理过程中对干法刻蚀具有良好的抗性。此外，即使在有机膜上形成CVD硬掩膜时，该组合物也不会因热分解导致膜厚波动。 用于形成有机膜的组合物包括： (A) 具有由以下一般式(1)表示的重复单元的聚合物； (B) 有机溶剂。
• Development of 5-Aminopyrazole-4-carboxamide-based Bumped-Kinase Inhibitors for Cryptosporidiosis Therapy
  作者：Wenlin Huang、Matthew A. Hulverson、Ryan Choi、Samuel L. M. Arnold、Zhongsheng Zhang、Molly C. McCloskey、Grant R. Whitman、Robert C. Hackman、Kasey L. Rivas、Lynn K. Barrett、Kayode K. Ojo、Wesley C. Van Voorhis、Erkang Fan

  DOI：10.1021/acs.jmedchem.9b00069

  日期：2019.3.28

  Cryptosporidium is a leading cause of pediatric diarrhea worldwide. Currently, there is neither a vaccine nor a consistently effective drug available for this disease. Selective 5-aminopyrazole-4-carboxamide-based bumped-kinase inhibitors (BKIs) are effective in both in vitro and in vivo models of Cryptosporidium parvum. Potential cardiotoxicity in some BKIs led to the continued exploration of the 5-aminopyrazole-4-carboxamide scaffold to find safe and effective drug candidates for Cryptosporidium. A series of newly designed BKIs were tested for efficacy against C. parvum using in vitro and in vivo (mouse infection model) assays and safety issues. Compound 6 (BKI 1708) was found to be efficacious at 8 mg/kg dosed once daily (QD) for 5 days with no observable signs of toxicity up to 200 mg/kg dosed QD for 7 days. Compound 15 (BKI 1770) was found to be efficacious at 30 mg/kg dosed twice daily (BID) for 5 days with no observable signs of toxicity up to 300 mg/kg dosed QD for 7 days. Compounds 6 and 15 are promising preclinical leads for cryptosporidiosis therapy with acceptable safety parameters and efficacy in the mouse model of cryptosporidiosis.